Get the Stockscreener App
0.549
4.59%
0.0241
After Hours:
.53
-0.019
-3.46%
Promis Neurosciences Inc stock is traded at $0.549, with a volume of 184.56K.
It is up +4.59% in the last 24 hours and down -50.98% over the past month.
ProMIS Neurosciences Inc is a clinical-stage biotechnology company focused on generating and developing antibody therapeutics selectively targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer's disease (AD), amyotrophic lateral sclerosis (ALS), and multiple system atrophy (MSA). The company applies its thermodynamic, computational discovery platform, ProMIS, and Collective Coordinates to predict novel targets known as Disease Specific Epitopes on the molecular surface of misfolded proteins.
See More
Previous Close:
$0.5249
Open:
$0.52
24h Volume:
184.56K
Relative Volume:
0.03
Market Cap:
$28.44M
Revenue:
-
Net Income/Loss:
$-563.30K
P/E Ratio:
-2.7505
EPS:
-0.1996
Net Cash Flow:
$-22.23M
1W Performance:
-12.86%
1M Performance:
-50.98%
6M Performance:
-32.64%
1Y Performance:
-55.37%
1-Day Range:
$0.52
$0.5514
1-Week Range:
$0.505
$0.6498
52-Week Range:
$0.38
$1.59
Promis Neurosciences Inc Stock (PMN) Company Profile
Name
Promis Neurosciences Inc
Sector
Industry
Phone
416-847-6898
Address
SUITE 200, 1920 YONGE STREET, TORONTO
Compare PMN with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
PMN
Promis Neurosciences Inc
|
0.549 | 20.17M | 0 | -563.30K | -22.23M | -0.1996 |
|
VRTX
Vertex Pharmaceuticals Inc
|
397.46 | 99.96B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
598.16 | 60.83B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
467.55 | 59.89B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
663.73 | 40.47B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
313.97 | 37.96B | 3.81B | -644.79M | -669.77M | -6.24 |
Promis Neurosciences Inc Stock (PMN) Latest News
ProMIS Neurosciences Reports Increased R&D Expenses and Net Loss - MSN
Promis Neurosciences chief scientific officer buys $14,595 in shares - MSN
ProMIS Neurosciences Announces $17.99M At The Market Offering to Enhance Financial Flexibility - AInvest
ProMIS Neurosciences Announces At The Market Offering - TipRanks
ProMIS Neurosciences Inc. Enters Reversal Setup in Weekly ChartsJuly 2025 Intraday Action & Risk Controlled Swing Alerts - kangso.co.kr
Candlestick Signal Suggests Reversal in ProMIS Neurosciences Inc.July 2025 Final Week & Free Fast Entry Momentum Trade Alerts - 선데이타임즈
Traders Consider Averaging Down in ProMIS Neurosciences Inc.2025 Fundamental Recap & Weekly High Conviction Trade Ideas - beatles.ru
Why ProMIS Neurosciences Inc. stock attracts strong analyst attentionJuly 2025 Pullbacks & High Win Rate Trade Tips - thegnnews.com
Market reaction to ProMIS Neurosciences Inc.’s recent newsStop Loss & Weekly Sector Rotation Insights - Newser
ProMIS Neurosciences: Promising Alzheimer's Treatment and Strong Financials Drive Buy Rating - AInvest
What makes ProMIS Neurosciences Inc. stock price move sharplyPortfolio Performance Summary & Free Long-Term Investment Growth Plans - Newser
ProMIS Neurosciences Inc. Building a Base Near Support2025 Market Sentiment & Safe Entry Momentum Tips - kangso.co.kr
Combining price and volume data for ProMIS Neurosciences Inc.July 2025 Action & Free Growth Oriented Trading Recommendations - Newser
Multi asset correlation models including ProMIS Neurosciences Inc.2025 Trade Ideas & Smart Swing Trading Techniques - Newser
ProMIS Neurosciences Reports Q2 2025 Financial Results, Receives FDA Fast Track Designation for PMN310. - AInvest
Leading vs lagging indicators on ProMIS Neurosciences Inc. performance2025 Trading Recap & Free Daily Entry Point Trade Alerts - Newser
ProMIS Neurosciences, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2025 - MarketScreener
ProMIS Neurosciences' Strategic Capital Raise and Long-Term Growth Potential - AInvest
Is ProMIS Neurosciences Inc. stock ready for a breakoutJuly 2025 Outlook & Intraday High Probability Setup Alerts - Newser
ProMIS Neurosciences: Navigating Capital-Intensive Risks for a Potential Alzheimer's Breakthrough - AInvest
ProMIS Neurosciences Reports Q2 GAAP EPS of -$0.29, Cash and Cash Equivalents at $4.5 Million - AInvest
ProMIS Neurosciences Inc. stock trend outlook and recovery pathJuly 2025 Price Swings & Weekly Hot Stock Watchlists - Newser
ProMIS Neurosciences Inc reports results for the quarter ended June 30Earnings Summary - TradingView
Chart overlay techniques for tracking ProMIS Neurosciences Inc.Weekly Trend Summary & High Accuracy Trade Signal Alerts - Newser
ProMIS Neurosciences Announces Second Quarter 2025 Financial Results & Corporate Highlights - Ariva
Published on: 2025-08-13 07:52:02 - Newser
ProMIS Neurosciences Q2 2025 Financial Results & Corporate Highlights - TradingView
ProMIS Neurosciences Inc. SEC 10-Q Report - TradingView
ProMIS Neurosciences receives FDA Fast Track designation for PMN310 in Alzheimer's disease. - AInvest
ProMIS Neurosciences Announces Q2 2025 Financial Results & Corporate Highlights: FDA Grants Fast Track Designation for PMN310 in Alzheimer’s Disease, PRECISE-AD Trial Progresses on Schedule, and Secures $21.6 Million in Gross Proceeds. - AInvest
Analyzing recovery setups for ProMIS Neurosciences Inc. investorsJuly 2025 Analyst Calls & Weekly Stock Breakout Alerts - Newser
Multi factor analysis applied to ProMIS Neurosciences Inc.Dividend Hike & Daily Entry Point Trade Alerts - Newser
Institutional scanner results for ProMIS Neurosciences Inc.Free Swing Setup With Technical Confirmation - Newser
ProMIS Neurosciences PMN 2025Q2 Earnings Preview Upside Ahead on Chinese Market Expansion - AInvest
Key metrics from ProMIS Neurosciences Inc.’s quarterly dataSwing Watchlist With Tight Stop Placement - Newser
Should I buy ProMIS Neurosciences Inc. stock before earningsFree Daily Top Performing Stock Insights - Newser
ProMIS Neurosciences Inc. stock momentum explainedPortfolio Building Plan and Summary Guide - Newser
Will ProMIS Neurosciences Inc. stock recover after recent dropTrade Safety Report with Pattern Insights - Newser
ProMIS Neurosciences Inc. stock daily chart insightsEntry Opportunity Screener with Confirmation - Newser
Is ProMIS Neurosciences Inc. forming a reversal patternSector-Wise Stock Strength Trend Analysis - Newser
Can swing trading help recover from ProMIS Neurosciences Inc. lossesStock Forecast Tools for Retail Traders - Newser
Intraday pattern recognizer results for ProMIS Neurosciences Inc.Momentum Trend Signal Weekly Recap Summary - Newser
How ProMIS Neurosciences Inc. stock performs during market volatilityBuy Strategy with Smart Exit Timing - Newser
Promis Neurosciences Inc Stock (PMN) Financials Data
Revenue
Net Income
Cash Flow
EPS
Promis Neurosciences Inc Stock (PMN) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Shafmaster Madge K. | Director |
Sep 24 '24 |
Buy |
1.30 |
70,000 |
91,028 |
208,333 |
| Shafmaster Madge K. | Director |
Sep 23 '24 |
Buy |
1.28 |
70,000 |
89,656 |
138,333 |
| Shafmaster Madge K. | Director |
Sep 20 '24 |
Buy |
1.25 |
60,000 |
75,066 |
68,333 |
| GORDON MICHAEL S | 10% Owner |
Sep 16 '24 |
Buy |
1.22 |
76,931 |
94,071 |
76,931 |
| GORDON MICHAEL S | 10% Owner |
Sep 17 '24 |
Buy |
1.40 |
16,292 |
22,809 |
93,223 |
1.55%
0.38%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):